Clinical trials in Heidelberg – page 8

739 clinical trials in Heidelberg, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Heidelberg at a glance

739

clinical trials

Research sites4

Quick filters

739 trials in Heidelberg

Open in trial search

Polyneuropathy

Recruiting

A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy

Registered drugNo placebo

A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Vutrisiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:AstraZeneca AB

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Gastrooesophageal cancer

Recruiting

Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

Registered drugNo placebo

Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hyperparathyroidism secondary

Recruiting

Phase 3 Evaluation of Etelcalcetide for Secondary Hyperparathyroidism in Pediatric Patients with Chronic Kidney Disease on Hemodialysis

Registered drugNo placebo

Phase 3 Evaluation of Etelcalcetide for Secondary Hyperparathyroidism in Pediatric Patients with Chronic Kidney Disease on Hemodialysis

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Etelcalcetide
Sponsor:Amgen Inc.

Contact Research Centre

Acute kidney injury

Recruiting

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Neuroendocrine carcinoma of the skin

Recruiting

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

Registered drug

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Hodgkin's disease

Recruiting

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:University Of Cologne

Contact Research Centre

Squamous cell carcinoma of lung+8

Recruiting

A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer

Registered drugNo placebo

A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:BNT326
Sponsor:BioNTech SE

Contact Research Centre

Neoplasm malignant+1

Recruiting

Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors

Registered drugNo placebo

Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fulvestrant
Sponsor:Novartis Pharma AG

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Bleximenib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Parkinson's disease

Recruiting

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Prasinezumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Heidelberg

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on heart failure prevention and treatment of TTR amyloidosis cardiovascular complications. Studies evaluating new therapeutic approaches for pulmonary hypertension.

Heart Disease Prevention
Cardiovascular Safety Studies
Amyloidosis Treatment

Research includes evaluation of novel compounds for heart conditions and preventive therapies.

02 Oncology Studies

Comprehensive research in lung cancer, bladder cancer, and melanoma treatments. Advanced trials for various lymphomas and leukemias using innovative therapeutic approaches.

Non-Small Cell Lung Cancer
Hematological Malignancies
Immunotherapy Combinations

Focus on targeted therapies and immunological approaches in cancer treatment.

03 Transplant Medicine

Groundbreaking research in kidney transplantation with innovative immune system modification approaches. Studies exploring new methods to improve transplant outcomes.

Living Donor Procedures
Immune System Modulation
Post-Transplant Care

Emphasis on developing personalized immunosuppression strategies.

Back to Germany All countries